CytomX Therapeutics (CTMX) Stock Price, Quote, News & History | Benzinga

CytomX Therapeutics Inc (CTMX) Stock Price, Quote, News & History

CTMXNASDAQ

Trade with Public

Trade with Public

$3.31

-0.11-3.25%

Last update: Aug 28, 12:24 PM

OverviewNews Earnings Forecast Events Price Targets Financials Sentiment Ownership Compare Options Stock Report

Key Statistics

Open

$3.40

Close

-

Volume / Avg.

554.50K / 3.95M

Day Range

$3.30 - $3.42

52 Wk Range

1.90 - 8.21

Market Cap

$720.99M

P/E Ratio

-

Dividend Yield

-

Exchange

NASDAQ

RSI

46

Short Interest

18.03%

Days to Cover

15.93

Recent CytomX Therapeutics, Inc. News

Why Is CytomX Therapeutics Stock Falling On Wednesday?

CytomX stock falls after $250 million share sale, even as new colorectal cancer data shows strong response and growth potential.

Vandana Singh

Mid-Cap CytomX Therapeutics' Colorectal Cancer Data Fuels Stock Rally

CytomX Therapeutics stock jumps in premarket trading after Phase 1 data for Varseta-M showed tumor responses in colorectal cancer patients.

Vandana Singh

Crude Oil Down 4%; Dollar Tree Earnings Top Views

Avi Kapoor

Nebius Group, CytomX Therapeutics, National Storage Affiliates Trust And Other Big Stocks Moving Higher On Monday

Dow Jones index up 500 points; Nebius Group NV shares rise 12.7% on AI agreement with Meta Platforms; several other stocks record gains.

Avi Kapoor

CytomX Therapeutics Gears Up For Q4 Print; Here Are The Recent Forecast Changes From Wall Street's Most Accurate Analysts

CytomX Therapeutics (CTMX) will release its Q4 earnings on March 16, with analysts expecting a loss of 9 cents per share. Stock fell 3.9% on Friday.

Avi Kapoor

Financials

Quarterly

Annual

Name

Revenue Change
Gross Change
EBITDA Change
EBIT Change
Earnings Change

Cash Flows

Operating Cash Flow (TTM)

-82.41M

Investing Cash Flow (TTM)

-200.80M

Financing Cash Flow (TTM)

251.89M

Free Cash Flow (TTM)

-82.48M

Capital Expenditure (TTM)

-

Net Change in Cash (TTM)

-31.32M

Analyst Trends and Forecast

8

Mar

1

May

2

Aug

Buy

Hold

Sell

Strong Sell

Analyst Rating and Forecast

3.9

Buy

Strong Buy

Buy

Hold

Sell

Strong Sell

Valuation Metrics

Enterprise Value

$420.64M

PE Ratio (TTM)

-

PE Ratio (FWD)

-

PEG Ratio (TTM)

-

PS Ratio (TTM)

34.18

PB Ratio (TTM)

2.47

Earnings Yield % (TTM)

-16.67%

Earnings Yield % (FWD)

-11.11%

EV / EBITDA (TTM)

-

Price / EBITDA (TTM)

-

Price / Free Cash Flow (TTM)

-

Book Value / Share

$1.39

Company Debt

Total Debt

-

LT Debt

-

LT Debt Issuance (TTM)

-

LT Debt Repayment (TTM)

-

Total Cash

$17.22M

Debt to Equity

0.02

Issuance of Debt (TTM)

-

Repayment of Debt (TTM)

-

Key Statistics

Open

$3.40

Close

-

Volume / Avg.

554.50K / 3.95M

Day Range

$3.30 - $3.42

52 Wk Range

1.90 - 8.21

Market Cap

$720.99M

P/E Ratio

-

Dividend Yield

-

Exchange

NASDAQ

RSI

46

Short Interest

18.03%

Days to Cover

15.93

About

Sector

Health Care

Industry

Biotechnology

CytomX Therapeutics Inc a clinical-stage, oncology-focused biopharmaceutical company developing novel, masked, conditionally activated biologics designed to be localized to the tumor microenvironment. It is engaged in developing antibody therapeutics...

Show More

Edge Rankings

Stock Score Locked: Want to See it?

Benzinga Rankings give you vital metrics on any stock – anytime.

Reveal Full Score

Compare

EPS worse than industry

Earnings Per Share

EPS is the portion of a company's profit allocated to each outstanding share of common stock. It is a key metric for investors to assess a company's profitability.

Earnings Per Share

EPS is the portion of a company's profit allocated to each outstanding share of common stock. It is a key metric for investors to assess a company's profitability.

EPS worse than industry

FAQ

Q

How do I buy CytomX Therapeutics (CTMX) stock?

A

You can purchase shares of CytomX Therapeutics (NASDAQ:CTMX) through any online brokerage.

View our list of the best stock brokerages

Q

Who are CytomX Therapeutics (CTMX) competitors?

A

Other companies in CytomX Therapeutics’s space includes: AbbVie Inc (NYSE:ABBV), Amgen Inc (NASDAQ:AMGN), Gilead Sciences Inc (NASDAQ:GILD), Vertex Pharmaceuticals Inc (NASDAQ:VRTX) and Regeneron Pharmaceuticals Inc (NASDAQ:REGN).

Q

What is the forecast, or price target, for CytomX Therapeutics (CTMX) stock?

A

CytomX Therapeutics has a consensus price target of $10.60.

Q

What is the current price for CytomX Therapeutics (CTMX)?

A

The stock price for CytomX Therapeutics (NASDAQ: CTMX) is $3.3088 last updated August 28, 2026 at 12:24 PM EDT.

Q

Does CytomX Therapeutics (CTMX) pay a dividend?

A

There are no upcoming dividends for CytomX Therapeutics.

Q

When is CytomX Therapeutics (NASDAQ:CTMX) reporting earnings?

A

CytomX Therapeutics does not have any upcoming earnings scheduled.

Q

Is CytomX Therapeutics (CTMX) going to split?

A

There is no upcoming split for CytomX Therapeutics.

Q

What sector and industry does CytomX Therapeutics (CTMX) operate in?

A

CytomX Therapeutics is in the Health Care sector and Biotechnology industry. They are listed on the NASDAQ.